Following on from @Titan19 & @LongTony comments above, a timely reminder for rusted-on longs and newbies alike, of the potential value of bisantrene in the AML market.
From RAC’s investor presentation November 2021https://www.raceoncology.com/wp-content/uploads/2021/12/Investor-Presentation-November-2021.pdf
estimated annual revenue for treatment of AML with bisantrene is ~$USD 300MPotential value
3.5 x sales = $USD 1.05 bill = $AUD 1.567 bill = $8.95/share (assume 175M SOI)4.0 x sales =$USD 1.2 bill = $AUD 1.791 bill = $10.23/share“
5.0 x sales =$USD 1.5 bill = $AUD 2.223 bill = $12.79/share“
So just for AMLalone, IMHO, the potential value is in therange of $8.95 - $12.79per share
Ann: Zantrene AML trial in Israel advances to Phase 2, page-105
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.58 |
Change
0.055(3.62%) |
Mkt cap ! $268.4M | |||
| Open | High | Low | Value | Volume |
| $1.56 | $1.61 | $1.56 | $106.0K | 67.13K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 649 | $1.58 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.59 | 3000 | 1 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| RAC (ASX) Chart |